Research on energy conversion characteristic of pump as turbine

by Senchun Miao, Junhu Yang, Fengxia Shi, Xiaohui Wang, Guangtai Shi
Published 2018-04-01

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

by Weidong Han, Malcolm Brock, Chunmeng Wang, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Jiejie Liu
Published 2021-04-01

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

by Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie, Weidong Han
Published 2021-07-01

Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

by Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie, Weidong Han
Published 2021-09-01

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

by Hui Fan, Xuechun Lu, Xiaohui Wang, Yang Liu, Bo Guo, Yan Zhang, Wenying Zhang, Jing Nie, Kaichao Feng, Meixia Chen, Yajing Zhang, Yao Wang, Fengxia Shi, Xiaobing Fu, Hongli Zhu, Weidong Han
Published 2014-01-01